Heart failure years after cancer treatment

Future Cardiology

Volumn 11, Issue 4, 2015, Pages 433-440

  Montoro, Nieves ^a   López Sendón, Jose Luis ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Cardiotoxicity; Heart failure; Left ventricular dysfunction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PREDNISOLONE; TROPONIN; VALSARTAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; HEART FAILURE; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HUMAN; INCIDENCE; LYMPHOMA; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; CHRONIC DISEASE; HEART LEFT VENTRICLE FUNCTION; NEOPLASMS; PREVENTION AND CONTROL; RISK FACTOR; TIME FACTOR;

ANTINEOPLASTIC AGENTS; CARDIOTOXICITY; CHRONIC DISEASE; HEART FAILURE; HUMANS; NEOPLASMS; PREVALENCE; RISK FACTORS; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84939429609     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.15.36     Document Type: Article

References (39)

1. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J. Clin. Oncol. 15(4), 1544-1552 (1997).
2. Carver JR, Shapiro CL, Ng A et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J. Clin. Oncol. 25(25), 3991-4008 (2007).
3. Curigliano G, Cardinale D, Suter T et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann. Oncol. 23(Suppl. 7), vii155-vii166 (2012).
4. Lancellotti P, Nkomo VT, Badano LP et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur. Heart J. Cardiovasc. Imaging 14(8), 721-740 (2013).
5. Plana JC, Galderisi M, Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 27(9), 911-939 (2014).
6. Oeffinger KC, Mertens AC, Sklar CA et al. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. 355(15), 1572-1582 (2006).
7. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 275(20), 1557-1562 (1996).
8. Mulrooney DA, Yeazel MW, Kawashima T et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339, b4606 (2009).
9. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J. Clin. Oncol. 25(25), 3808-3815 (2007).
10. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11), 2869-2879 (2003).
11. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 53(24), 2231-2247 (2009).
12. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J. Clin. Oncol. 23(13), 2900-2902 (2005).
13. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J. Am. Coll. Cardiol. 55(3), 213-220 (2010).
14. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J. Clin. Oncol. 23(34), 8597-8605 (2005).
15. Darby SC, Cutter DJ, Boerma M et al. Radiation-related heart disease: current knowledge and future prospects. Int. J. Radiat. Oncol. Biol. Phys. 76(3), 656-665 (2010).
16. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270(16), 1949-1955 (1993).
17. Meyer RM, Gospodarowicz MK, Connors JM et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N. Engl. J. Med. 366(5), 399-408 (2012).
18. Shapiro CL, Hardenbergh PH, Gelman R et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J. Clin. Oncol. 16(11), 3493-3501 (1998).
19. Schultz-Hector S, Trott KR. Radiationinduced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int. J. Radiat. Oncol. Biol. Phys. 67(1), 10-18 (2007).
20. Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125(1), e2-e220 (2012).
21. Smith LA, Cornelius VR, Plummer CJ et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10, 337 (2010).
22. Kim YH, Park SM, Kim M et al. Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats. Toxicol. Mech. Methods 22(6), 488-498 (2012).
23. Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J. Am. Coll. Cardiol. 60(23), 2384-2390 (2012).
24. Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J. Mol. Cell. Cardiol. 19(8), 817-828 (1987).
25. Toko H, Oka T, Zou Y et al. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens. Res. 25(4), 597-603 (2002).
26. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114(23), 2474-2481 (2006).
27. Nakamae H, Tsumura K, Terada Y et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104(11), 2492-2498 (2005).
28. Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracyclineinduced cardiomyopathy. J. Am. Coll. Cardiol. 48(11), 2258-2262 (2006).
29. Bosch X, Rovira M, Sitges M et al. Enalapril and carvedilol for preventing chemotherapyinduced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J. Am. Coll. Cardiol. 61(23), 2355-2362 (2013).
30. Swain SM, Whaley FS, Gerber MC et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. 15(4), 1318-1332 (1997).
31. Venturini M, Michelotti A, Del Mastro L et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J. Clin. Oncol. 14(12), 3112-3120 (1996).
32. Lipshultz SE, Rifai N, Dalton VM et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N. Engl. J. Med. 351(2), 145-153 (2004).
33. Cvetkovic RS, Scott LJ. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 65(7), 1005-1024 (2005).
34. Eschenhagen T, Force T, Ewer MS et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 13(1), 1-10 (2011).
35. Mcmurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 14(8), 803-869 (2012).
36. Lancellotti P, Anker SD, Donal E et al. EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/ HFA COT Registry)-EURObservational Research Program of the European Society of Cardiology. Eur. Heart J. Cardiovasc. Imaging 16(5), 466-470 (2015).
37. Visscher H, Ross CJ, Rassekh SR et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J. Clin. Oncol. 30(13), 1422-1428 (2012).
38. Marinko T, Dolenc J, Bilban-Jakopin C. Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer. Radiol. Oncol. 48(2), 105-112 (2014).
39. Mouhayar E, Durand JB, Cortes J. Cardiovascular toxicity of tyrosine kinase inhibitors. Expert Opin. Drug Saf. 12(5), 687-696 (2013).